Status:
COMPLETED
Safety of Fondaparinux as Post Partum Thromboprophylaxis
Lead Sponsor:
National University of Malaysia
Conditions:
Thromboembolism in the Puerperium
Eligibility:
FEMALE
18+ years
Phase:
PHASE4
Brief Summary
Venous thromboembolism (VTE) remains as one of leading causes of maternal morbidity and mortality, with postpartum period carries the greatest risk. Perinatal thromboprophylaxis is often administered ...
Detailed Description
All women were taught the injection technique and counselled regarding the symptoms of bleeding and VTE, prior to discharge. All patients were also advised to wear compression stockings and ensure ade...
Eligibility Criteria
Inclusion
- Malaysian
- Age 18 and above
- Scores asintermediate risk on 2015 Royal College of Obstetricians \& Gynaecologists (RCOG) VTE risk assessment
Exclusion
- Hypersensitivity to fondaparinux
- Patients with bleeding disorders - haemophilia , thrombocytopenia, von Willebrand's disease.
- Weight \< 50 kg
- Patients with primary postpartum haemorrhage
- Patients who already on anti - coagulants
- Medical co morbidities - Systemic lupus erythematosus, heart failure, nephrotic syndrome, type 1 diabetes mellitus with nephropathy, sickle cell disease, current intravenous drug user
- Uncontrolled hypertension ( blood pressure \> 200 mmHg systolic or \> 120 mmHg diastolic )
Key Trial Info
Start Date :
September 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2018
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04447378
Start Date
September 1 2017
End Date
June 1 2018
Last Update
June 26 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Obstetrics & Gynaecology, Universiti Kebangsaan Medical Centre
Cheras, Kuala Lumpur, Malaysia, 56000